Investments
70Portfolio Exits
19Funds
3About Global Life Science Ventures
GLSV is an independent venture capital fund focusingexclusively on the life sciences. With offices in Switzerland andGermany, GLSV is dedicated to supporting early-stage companiesoriginating from universities, scientific institutions or industry,but also invests in selected later-stage companies, includingbuy-outs. The group currently advises aims to manage funds totaling morethan EUR 200 million. GLSV has now financed 33 innovative life sciencecompanies throughout Europe and the USA, thirteen of which havecompleted an exit through IPO, trade sale or M&A. Since 1996, GLSVhas built up a broadly diversified portfolio of companies inpharmaceuticals, diagnostics, medical devices, and biotechnology.Global Life Science Ventures Industry-born team - Proven track record - Global perspective.
Global Life Science Ventures Headquarter Location
Tal 26
Munich, D-80331,
Germany
Latest Global Life Science Ventures News
Jan 15, 2015
Global Life Science Ventures GmbH - Medical Equipment - Investment Profile LifeScience Alley announces today that 86 Minnesota-based companies within the life science industry collectively raised $430.4 million in 2014, representing the highest level of investment activity in the industry since 2009. Investments in Minnesota’s medical device sector reached a six year high at $322 million, a 6.3% increase over 2013. “2014 was a record year for all life science investing activity and within many of the individual sectors we cover,” said Cheryl Matter, PhD, director of intelligence and research for LifeScience Alley. “The data and increasing trends over the last six years indicate that Minnesota's life science industry is healthy and growing, and that investment opportunities still abound to help these companies. " These findings come from LifeScience Alley’s "Minnesota Life Science Investment Activity" report series, which compiles quarterly data on a variety of investment types from various sources for early-stage and emerging companies in the medical device, pharmaceuticals and biotechnology , health information technology, and diagnostics and research tools sectors. Total 2014 life science investing was up $81.8 million, a 23% increase over 2013 and a 71% increase over 2012. Although medical device companies attracted record high investment dollars, 2014 saw increased diversification of sectors securing investment, with significant spikes in both the number of companies receiving funds and total dollars invested within the pharmaceuticals/biotechnology and health information technology sectors. Raising $49 million, the pharmaceuticals and biotechnology sector saw a 10-fold increase over 2013 investment levels ($4 million). Minnesota's rapidly growing health information technology sector saw investment levels up 41% over 2013 at $41 million raised, continuing an increasing trend in that space. Another trend driving investment growth is the increase in companies raising large figures. This year, 17 companies raised $7 million or more (compared to 11 companies in 2013) and 26 companies raised $3 million or more (compared to 22 companies in 2013). The medical device sector accounted for 71% of the companies raising $7 million or more. 2014 also saw the highest median levels of investing activity yet, with a median of $3.9 million in quarter three and $2.4 million in quarter four. For the first time during the years tracked, the fourth quarter saw higher investment levels than the historically strongest third quarter, with $119 million raised, a 17% increase over 2013. In addition to recording high levels of life science investment activity, 2014 saw more than $1 billion in liquidity events in the life science industry, with transactions in the health information technology sector accounting for approximately $780 million. About LifeScience Alley LifeScience Alley is a global leader in enabling life science business success with a 30-year track record of delivering results-oriented outcomes. We are committed to leading the conversation in improving our community’s operating environment and supporting advancement in research and healthcare innovation. By influencing proactive policy change, delivering vital information and intelligence, leading solutions-based initiatives and uniting members with critical resources, LifeScience Alley works to ensure that collectively Minnesota’s Medical Alley remains the world's strongest health technology community. The Association’s membership and supporting community extends throughout the world, employing more than 300,000 Minnesotans and many more globally. Learn more at www.LifeScienceAlley.org . LifeScience Alley
Global Life Science Ventures Investments
70 Investments
Global Life Science Ventures has made 70 investments. Their latest investment was in Nabriva Therapeutics as part of their Series B on April 4, 2015.
Global Life Science Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/7/2015 | Series B | Nabriva Therapeutics | $120M | No | 5 | |
6/22/2012 | Convertible Note | Santaris Pharma | $12M | No | ||
1/1/2012 | Series A | Pixium | $11.9M | Yes | 1 | |
12/11/2009 | Debt | |||||
10/28/2009 | Series A |
Date | 4/7/2015 | 6/22/2012 | 1/1/2012 | 12/11/2009 | 10/28/2009 |
---|---|---|---|---|---|
Round | Series B | Convertible Note | Series A | Debt | Series A |
Company | Nabriva Therapeutics | Santaris Pharma | Pixium | ||
Amount | $120M | $12M | $11.9M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 5 | 1 |
Global Life Science Ventures Portfolio Exits
19 Portfolio Exits
Global Life Science Ventures has 19 portfolio exits. Their latest portfolio exit was Nabriva Therapeutics on September 18, 2015.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/18/2015 | IPO | Public | 1 | ||
12/18/2014 | Reverse Merger | 2 | |||
8/4/2014 | Acquired | 1 | |||
Date | 9/18/2015 | 12/18/2014 | 8/4/2014 | ||
---|---|---|---|---|---|
Exit | IPO | Reverse Merger | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 2 | 1 |
Global Life Science Ventures Fund History
3 Fund Histories
Global Life Science Ventures has 3 funds, including Global Life Science Ventures Fonds II LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
12/31/2002 | Global Life Science Ventures Fonds II LP | Multi-Stage Venture Capital | Closed | $180M | 1 |
12/31/1996 | Global Life Science Fund LP | ||||
Global Life Science Ventures Fonds III LP |
Closing Date | 12/31/2002 | 12/31/1996 | |
---|---|---|---|
Fund | Global Life Science Ventures Fonds II LP | Global Life Science Fund LP | Global Life Science Ventures Fonds III LP |
Fund Type | Multi-Stage Venture Capital | ||
Status | Closed | ||
Amount | $180M | ||
Sources | 1 |
Global Life Science Ventures Team
1 Team Member
Global Life Science Ventures has 1 team member, including former Controller, Ralf Johnsen.
Name | Work History | Title | Status |
---|---|---|---|
Ralf Johnsen | Controller | Former |
Name | Ralf Johnsen |
---|---|
Work History | |
Title | Controller |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.